AbbVie’s most recent migraine market entrant, Qulipta, showing strongest growth 

All seven CGRP inhibitors on the market had sales growth last quarter, with oral therapies from Pfizer and AbbVie the top performers

Nurtec ODT and Ubrelvy lead the pack, while subcutaneous and intravenous therapies take a back seat

Amgen’s first-mover advantage among CGRP therapies for migraine appears to have been overcome, as both Eli Lilly’s Emgality and AbbVie’s Ubrelvy surpassed

With little difference in efficacy or price, the CGRP competition will boil down to delivery, frequency and access